Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Radiotherapy in HER2+ High-Risk NMIBC
NCT07100184Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in non-muscle-invasive bladder cancer (NMIBC), sponsored by Peking University First Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07100184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100184.